TEVA PHARMACEUTICAL-SP ADR (TEVA)
US8816242098 - ADR
We assign a fundamental rating of 5 out of 10 to TEVA. TEVA was compared to 198 industry peers in the Pharmaceuticals industry. TEVA has an excellent profitability rating, but there are concerns on its financial health. TEVA is valued quite cheap, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year TEVA was profitable.
In the past year TEVA had a positive cash flow from operations.
In the past 5 years TEVA reported 4 times negative net income.
Each year in the past 5 years TEVA had a positive operating cash flow.
1.2 Ratios
TEVA has a better Return On Assets (-1.29%) than 80.61% of its industry peers.
TEVA has a Return On Equity of -7.45%. This is amongst the best in the industry. TEVA outperforms 80.10% of its industry peers.
The Return On Invested Capital of TEVA (9.02%) is better than 89.29% of its industry peers.
The Average Return On Invested Capital over the past 3 years for TEVA is significantly below the industry average of 16.71%.
The 3 year average ROIC (8.01%) for TEVA is below the current ROIC(9.02%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.29% | ||
| ROE | -7.45% | ||
| ROIC | 9.02% |
ROA(3y)-1.99%
ROA(5y)-3.12%
ROE(3y)-11.58%
ROE(5y)-16.34%
ROIC(3y)8.01%
ROIC(5y)7.1%
1.3 Margins
TEVA's Operating Margin of 22.53% is amongst the best of the industry. TEVA outperforms 90.31% of its industry peers.
TEVA's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 50.33%, TEVA is in the better half of the industry, outperforming 61.73% of the companies in the same industry.
TEVA's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 22.53% | ||
| PM (TTM) | N/A | ||
| GM | 50.33% |
OM growth 3Y5.53%
OM growth 5Y5.95%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.49%
GM growth 5Y2.73%
2. Health
2.1 Basic Checks
TEVA has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for TEVA remains at a similar level compared to 1 year ago.
TEVA has more shares outstanding than it did 5 years ago.
The debt/assets ratio for TEVA has been reduced compared to a year ago.
2.2 Solvency
TEVA has an Altman-Z score of 0.45. This is a bad value and indicates that TEVA is not financially healthy and even has some risk of bankruptcy.
TEVA has a Altman-Z score (0.45) which is comparable to the rest of the industry.
TEVA has a debt to FCF ratio of 23.55. This is a negative value and a sign of low solvency as TEVA would need 23.55 years to pay back of all of its debts.
TEVA's Debt to FCF ratio of 23.55 is fine compared to the rest of the industry. TEVA outperforms 79.08% of its industry peers.
TEVA has a Debt/Equity ratio of 2.42. This is a high value indicating a heavy dependency on external financing.
TEVA has a worse Debt to Equity ratio (2.42) than 81.12% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.42 | ||
| Debt/FCF | 23.55 | ||
| Altman-Z | 0.45 |
ROIC/WACC1.29
WACC6.99%
2.3 Liquidity
TEVA has a Current Ratio of 1.02. This is a normal value and indicates that TEVA is financially healthy and should not expect problems in meeting its short term obligations.
TEVA has a worse Current ratio (1.02) than 86.73% of its industry peers.
A Quick Ratio of 0.69 indicates that TEVA may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.69, TEVA is doing worse than 86.73% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.02 | ||
| Quick Ratio | 0.69 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 1.19% over the past year.
The Revenue has been growing slightly by 6.16% in the past year.
TEVA shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -3.42% yearly.
EPS 1Y (TTM)1.19%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q40.85%
Revenue 1Y (TTM)6.16%
Revenue growth 3Y-1.65%
Revenue growth 5Y-3.42%
Revenue growth Q2Q14.75%
3.2 Future
Based on estimates for the next years, TEVA will show a small growth in Earnings Per Share. The EPS will grow by 3.00% on average per year.
Based on estimates for the next years, TEVA will show a small growth in Revenue. The Revenue will grow by 2.64% on average per year.
EPS Next Y-5.32%
EPS Next 2Y1.78%
EPS Next 3Y3%
EPS Next 5YN/A
Revenue Next Year2.72%
Revenue Next 2Y2.73%
Revenue Next 3Y2.64%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 5.17, the valuation of TEVA can be described as very cheap.
TEVA's Price/Earnings ratio is rather cheap when compared to the industry. TEVA is cheaper than 96.43% of the companies in the same industry.
TEVA is valuated cheaply when we compare the Price/Earnings ratio to 25.05, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 5.47, the valuation of TEVA can be described as very cheap.
Compared to the rest of the industry, the Price/Forward Earnings ratio of TEVA indicates a rather cheap valuation: TEVA is cheaper than 98.47% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of TEVA to the average of the S&P500 Index (21.53), we can say TEVA is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.17 | ||
| Fwd PE | 5.47 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, TEVA is valued cheaply inside the industry as 94.90% of the companies are valued more expensively.
84.69% of the companies in the same industry are more expensive than TEVA, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.61 | ||
| EV/EBITDA | 6.67 |
4.3 Compensation for Growth
The decent profitability rating of TEVA may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.78%
EPS Next 3Y3%
5. Dividend
5.1 Amount
TEVA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TEVA PHARMACEUTICAL-SP ADR
NYSE:TEVA (4/15/2024, 4:39:36 PM)
After market: 13.16 -0.07 (-0.53%)13.23
-0.07 (-0.53%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap14.83B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.17 | ||
| Fwd PE | 5.47 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.29% | ||
| ROE | -7.45% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 22.53% | ||
| PM (TTM) | N/A | ||
| GM | 50.33% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.36
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.42 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.02 | ||
| Quick Ratio | 0.69 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)1.19%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-5.32%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)6.16%
Revenue growth 3Y-1.65%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y